Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones
CompanyDeals

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Vir Biotechnology, Inc. (NASDAQ: VIR) announced a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO‑XTEN dual‑masked T‑cell engager (TCE) development candidates targeting selected solid…

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development
Company

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma
CompanyDrug

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available
CompanyDrug

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

- Advertisement -
Ad image
CompanyDrug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

CompanyDrug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

CompanyDrug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

CompanyDrug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

CompanyDrug

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
CompanyDrug

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment
CompanyDrug

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment

CompanyDrug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

CompanyDrug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

CompanyDeals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

CompanyDeals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Show More